Sobejana M, Al Beiramani M, Zwezerijnen G, van der Kooi A, Raaphorst J, Meskers C
Biomedicines. 2025; 13(2).
PMID: 40002878
PMC: 11853360.
DOI: 10.3390/biomedicines13020465.
Mohymen A, Farag H, Reda S, Monem A, Ali S
J Med Phys. 2025; 49(4):597-607.
PMID: 39926131
PMC: 11801078.
DOI: 10.4103/jmp.jmp_123_24.
Park Y, Choi J, Lee H, Moon S, Lee I, Lee J
Nucl Med Mol Imaging. 2025; 59(1):41-49.
PMID: 39881969
PMC: 11772901.
DOI: 10.1007/s13139-024-00899-6.
Jorgensen K, Hoi-Hansen F, Loos R, Hinge C, Andersen F
Diagnostics (Basel). 2025; 14(24.
PMID: 39767147
PMC: 11727111.
DOI: 10.3390/diagnostics14242786.
Yang Y, Chen Z, Qiu Y, Cheng J, Na R, Liu M
Front Med (Lausanne). 2025; 11:1474698.
PMID: 39744536
PMC: 11688604.
DOI: 10.3389/fmed.2024.1474698.
Performance of PSMA-PET/CT as verified by bone biopsy for diagnosing osseous metastases of prostate cancer.
Ou W, Jennings J, Northrup B, Dettorre G, Winkler W, Imaoka R
Skeletal Radiol. 2024; .
PMID: 39704796
DOI: 10.1007/s00256-024-04855-5.
Predictive value of F-fluorodeoxyglucose uptake for axillary lymph node metastasis in operable breast cancer: impact of molecular subtypes.
Lim C, Lee J, Lee J, Park S
Ann Nucl Med. 2024; .
PMID: 39623100
DOI: 10.1007/s12149-024-02002-7.
Whole-body PET image denoising for reduced acquisition time.
Kruzhilov I, Kudin S, Vetoshkin L, Sokolova E, Kokh V
Front Med (Lausanne). 2024; 11:1415058.
PMID: 39403284
PMC: 11471667.
DOI: 10.3389/fmed.2024.1415058.
Activity quantification and dosimetry in radiopharmaceutical therapy with reference to Lutetium.
Ramonaheng K, Qebetu M, Ndlovu H, Swanepoel C, Smith L, Mdanda S
Front Nucl Med. 2024; 4:1355912.
PMID: 39355215
PMC: 11440950.
DOI: 10.3389/fnume.2024.1355912.
Active monitoring improves radiopharmaceutical administration quality.
Crowley J, Barvi I, Kiser J
Front Nucl Med. 2024; 3:1126029.
PMID: 39355027
PMC: 11440977.
DOI: 10.3389/fnume.2023.1126029.
Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics.
Roberts M, Papa N, Veerman H, de Bie K, Morton A, Franklin A
BJU Int. 2024; 134 Suppl 2:47-55.
PMID: 39262180
PMC: 11603102.
DOI: 10.1111/bju.16482.
Application of Dynamic [F]FDG PET/CT Multiparametric Imaging Leads to an Improved Differentiation of Benign and Malignant Lung Lesions.
Zhao Y, Lv T, Xu Y, Yin J, Wang X, Xue Y
Mol Imaging Biol. 2024; 26(5):790-801.
PMID: 39174787
DOI: 10.1007/s11307-024-01942-w.
Quantitative Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following Lu-PSMA-617 (VISION Trial).
Kuo P, Morris M, Hesterman J, Kendi A, Rahbar K, Wei X
Radiology. 2024; 312(2):e233460.
PMID: 39162634
PMC: 11366674.
DOI: 10.1148/radiol.233460.
Clinical Performance Comparison of a Long Versus a Short Axial Field-of-View PET/CT Using EARL-Compliant Reconstructions.
Roya M, van Snick J, Slart R, Noordzij W, Stormezand G, Willemsen A
Mol Imaging Biol. 2024; 26(5):780-789.
PMID: 39093483
PMC: 11436434.
DOI: 10.1007/s11307-024-01939-5.
The pons as an optimal background reference region for spinal F-FET PET/MRI evaluation.
Huang J, Wang J, Cui B, Yang H, Tian D, Ma J
EJNMMI Res. 2024; 14(1):69.
PMID: 39060564
PMC: 11282009.
DOI: 10.1186/s13550-024-01130-5.
Meta-analysis of [F]FDG-PET/CT in pulmonary sarcoidosis.
Donnelly R, McDermott M, McManus G, Franciosi A, Keane M, McGrath E
Eur Radiol. 2024; .
PMID: 39044038
DOI: 10.1007/s00330-024-10949-4.
Comparison of digital and analog [Ga]Ga-PSMA-11 PET/CT for detecting post-prostatectomy biochemical recurrence in prostate cancer patients: a prospective study.
Kim Y, Lee D, Sung C, Lee S, Oh S, Oh J
Sci Rep. 2024; 14(1):14989.
PMID: 38951530
PMC: 11217435.
DOI: 10.1038/s41598-024-65399-1.
Multi-level tuberculosis of the spine identified by 18 F-FDG-PET/CT and concomitant urogenital tuberculosis: a case report from the spinal TB X cohort.
Scherer J, Mukasa S, Wolmarans K, Guler R, Kotze T, Song T
Infection. 2024; 52(6):2507-2519.
PMID: 38896371
PMC: 11621135.
DOI: 10.1007/s15010-024-02327-5.
The Association between the Body Mass Index, Chronic Obstructive Pulmonary Disease and SUV of the Non-Tumorous Lung in the Pretreatment [F]FDG-PET/CT of Patients with Lung Cancer.
Wehlte L, Walter J, Daisenberger L, Kuhnle F, Ingenerf M, Schmid-Tannwald C
Diagnostics (Basel). 2024; 14(11).
PMID: 38893665
PMC: 11171792.
DOI: 10.3390/diagnostics14111139.
Can FDG-PET/CT imaging be used to predict decline in quality of life in interstitial lung disease? A prospective study of the relationship between FDG uptake and quality of life in a UK outpatient setting.
Jordon L, Ganeshan B, Nadeem I, Hoy L, Mahdi N, Porter J
BMJ Open. 2024; 14(5):e081103.
PMID: 38816048
PMC: 11141197.
DOI: 10.1136/bmjopen-2023-081103.